137 related articles for article (PubMed ID: 8245523)
1. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
Belshe RB; Clements ML; Dolin R; Graham BS; McElrath J; Gorse GJ; Schwartz D; Keefer MC; Wright P; Corey L
J Infect Dis; 1993 Dec; 168(6):1387-95. PubMed ID: 8245523
[TBL] [Abstract][Full Text] [Related]
2. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
[TBL] [Abstract][Full Text] [Related]
4. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Newman FK; Belshe RB
J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960
[TBL] [Abstract][Full Text] [Related]
5. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
[TBL] [Abstract][Full Text] [Related]
7. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Schwartz DH; Graham BS; Matthews TJ; Stablein DM; Frey SE; Belshe RB; Clements ML; Wright PF; Eibl M
Clin Exp Immunol; 1994 Nov; 98(2):178-84. PubMed ID: 7955519
[TBL] [Abstract][Full Text] [Related]
9. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
Dolin R; Graham BS; Greenberg SB; Tacket CO; Belshe RB; Midthun K; Clements ML; Gorse GJ; Horgan BW; Atmar RL
Ann Intern Med; 1991 Jan; 114(2):119-27. PubMed ID: 1984386
[TBL] [Abstract][Full Text] [Related]
10. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
[TBL] [Abstract][Full Text] [Related]
11. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
Parry C; McLain L; Dimmock NJ
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
13. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
[TBL] [Abstract][Full Text] [Related]
14. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
[TBL] [Abstract][Full Text] [Related]
15. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
Graham BS; Gorse GJ; Schwartz DH; Keefer MC; McElrath MJ; Matthews TJ; Wright PF; Belshe RB; Clements ML; Dolin R
J Infect Dis; 1994 Oct; 170(4):782-6. PubMed ID: 7930718
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Belshe RB; Newman FK; Frey SE
Vaccine; 1992; 10(6):383-8. PubMed ID: 1534641
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.
Graham BS; Belshe RB; Clements ML; Dolin R; Corey L; Wright PF; Gorse GJ; Midthun K; Keefer MC; Roberts NJ
J Infect Dis; 1992 Aug; 166(2):244-52. PubMed ID: 1353102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
